COVID-19 leads to sharp rise in stress cardiomyopathy

The ongoing COVID-19 pandemic has led to a significant increase in the number of patients presenting with stress cardiomyopathy, according to new findings published in JAMA Open Network.

The authors tracked nearly 2,000 acute coronary syndrome patients who received care at one of two Ohio hospitals. Patients treated during the pandemic—March 1 to April 30, 2020—were compared with patients treated during four other two-month periods from March 2018 to February 2020.

Stress cardiomyopathy—often referred to as broken heart syndrome—was up significantly in March and April 2020, reaching a rate of 7.8%. Prior to the pandemic, the stress cardiomyopathy rates ranged from 1.5% to 1.8%.

The researchers noted, however, that the patients diagnosed with this condition all tested negative for COVID-19. Also, the likelihood of mortality or a 30-day rehospitalization do not appear to have been affected by the pandemic.

“The COVID-19 pandemic has brought about multiple levels of stress in people's lives across the country and world,” lead author Ankur Kalra, MD, a Cleveland Clinic cardiologist, said in a statement. “People are not only worried about themselves or their families becoming ill, they are dealing with economic and emotional issues, societal problems and potential loneliness and isolation. The stress can have physical effects on our bodies and our hearts, as evidenced by the increasing diagnoses of stress cardiomyopathy we are experiencing.”

“For those who feel overwhelmed by stress, it's important to reach out to your healthcare provider,” added senior author Grant Reed, MD, MSc, director of Cleveland Clinic’s STEMI program. “Exercise, meditation and connecting with family and friends, while maintaining physical distance and safety measures, can also help relieve anxiety.”

The full study is available here.

Find more cardiology related COVID stories

 

Related Cardiomyopathy Content:

U.S. expected to see large rise in cardiomyopathy cases over next decade

FDA approves mavacamten for obstructive hypertrophic cardiomyopathy

American Heart Association, American College of Cardiology share updated guidance on hypertrophic cardiomyopathy

Metoprolol demonstrates value as a treatment for obstructive hypertrophic cardiomyopathy

Diabetes with cardiomyopathy associated with heightened heart failure risk

‘Surprising’ trends in ICD use among HCM patients

Combined genetic testing for cardiomyopathies and arrhythmias yields positive results

LAA occlusion reduces stroke risk among patients with HCM and AFib

MRI detects heart failure risk in patients with dilated cardiomyopathy

Michael Walter
Michael Walter, Managing Editor

Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup